← All trials
NCT05024045
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2021
- Primary completion
- Apr 30, 2024
- Completion date
- Apr 30, 2024
- First posted
- Aug 27, 2021
- Last posted
- Nov 22, 2021
- Enrollment
- 286
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Eli LillyLead sponsor
- Loxo OncologyStudy director
- Loxo OncologyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.